Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831765 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,290
- Enrollment target
NCT01831765 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,290 participants.
The verdict
NCT01831765, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,290 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in adults with type 1 diabetes. This trial consists of two periods: a 26 week treatment period followed by a 26 week additional treatment period.
Interventions
- DRUG insulin aspart
- DRUG insulin detemir
- DRUG Faster-acting insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,290 participants |
| Start Date | 2013-08-26 |
| Est. Completion | 2015-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01831765
The ClinicalTrials.gov registry entry for NCT01831765 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT01831765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01831765 about?
NCT01831765 is a clinical study titled "Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes". This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in adults with type 1 diabetes. This trial consists of two...
What is the current status of trial NCT01831765?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,290 participants. The study started on 2013-08-26. Estimated completion is 2015-06-11.
What interventions are being tested in trial NCT01831765?
The interventions under investigation include: insulin aspart (DRUG), insulin detemir (DRUG), Faster-acting insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01831765?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.